Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HURA NASDAQ:HYPD NASDAQ:IVVD NASDAQ:MEIP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHURATuHURA Biosciences$2.53-2.5%$2.67$1.80▼$8.40$126.62M-0.1302,157 shs108,415 shsHYPDHyperion DeFi$13.42+11.9%$8.97$0.85▼$47.33$76.36M2.51.94 million shs1.86 million shsIVVDInvivyd$1.41+14.2%$0.81$0.35▼$2.74$168.80M0.557.95 million shs7.85 million shsMEIPMEI Pharma$3.19+14.7%$4.59$1.46▼$9.00$104.72M0.381.15 million shs3.98 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHURATuHURA Biosciences+9.28%+2.37%-20.31%+5.28%+258,999,900.00%HYPDHyperion DeFi+13.11%+95.28%+65.84%+391.39%-73.38%IVVDInvivyd-4.65%+23.31%+57.63%+55.30%+20.59%MEIPMEI Pharma+3.88%-25.32%-33.42%+39.26%+5.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHURATuHURA Biosciences$2.53-2.5%$2.67$1.80▼$8.40$126.62M-0.1302,157 shs108,415 shsHYPDHyperion DeFi$13.42+11.9%$8.97$0.85▼$47.33$76.36M2.51.94 million shs1.86 million shsIVVDInvivyd$1.41+14.2%$0.81$0.35▼$2.74$168.80M0.557.95 million shs7.85 million shsMEIPMEI Pharma$3.19+14.7%$4.59$1.46▼$9.00$104.72M0.381.15 million shs3.98 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHURATuHURA Biosciences+9.28%+2.37%-20.31%+5.28%+258,999,900.00%HYPDHyperion DeFi+13.11%+95.28%+65.84%+391.39%-73.38%IVVDInvivyd-4.65%+23.31%+57.63%+55.30%+20.59%MEIPMEI Pharma+3.88%-25.32%-33.42%+39.26%+5.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHURATuHURA Biosciences 3.40Buy$12.67401.65% UpsideHYPDHyperion DeFi 2.00Hold$2.00-85.10% DownsideIVVDInvivyd 3.25Buy$3.18126.57% UpsideMEIPMEI Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HYPD, MEIP, IVVD, and HURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $1.008/15/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $3.006/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/26/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AHYPDHyperion DeFi$60K1,272.66N/AN/A($695.52) per share-0.02IVVDInvivyd$25.38M6.65N/AN/A$0.56 per share2.51MEIPMEI PharmaN/AN/A$6.25 per share0.51$4.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A-248.79%-150.83%10/6/2025 (Estimated)HYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/AIVVDInvivyd-$169.93M-$0.92N/A12.77N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/18/2025 (Estimated)Latest HYPD, MEIP, IVVD, and HURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HURATuHURA Biosciences-$0.14-$0.21-$0.07-$0.21N/AN/A8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/13/2025Q2 2025HYPDHyperion DeFiN/A-$2.50N/A-$2.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHURATuHURA BiosciencesN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHURATuHURA BiosciencesN/A0.830.83HYPDHyperion DeFi0.200.910.91IVVDInvivydN/A1.331.33MEIPMEI PharmaN/A16.7816.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHURATuHURA Biosciences0.62%HYPDHyperion DeFi25.84%IVVDInvivyd70.36%MEIPMEI Pharma52.38%Insider OwnershipCompanyInsider OwnershipHURATuHURA Biosciences0.20%HYPDHyperion DeFi10.86%IVVDInvivyd25.40%MEIPMEI Pharma3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHURATuHURA BiosciencesN/A50.05 million49.95 millionN/AHYPDHyperion DeFi405.69 million5.08 millionNo DataIVVDInvivyd100120.14 million89.63 millionOptionableMEIPMEI Pharma10032.84 million31.81 millionOptionableHYPD, MEIP, IVVD, and HURA HeadlinesRecent News About These CompaniesMEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’September 11 at 4:16 AM | theglobeandmail.comMEI Pharma to change name to Lite StrategySeptember 10 at 6:14 PM | msn.comMEI Pharma leaves biotech woes behind to rebrand as crypto companySeptember 10 at 6:14 PM | fiercebiotech.comFMEI Pharma (NASDAQ:MEIP) Rating Lowered to "Sell" at Wall Street ZenSeptember 8, 2025 | marketbeat.comMEI Pharma (NASDAQ:MEIP) Rating Lowered to Sell at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comMEI Pharma Secures Loan Agreement with BitGo PrimeSeptember 4, 2025 | msn.comWall Street Zen Upgrades MEI Pharma (NASDAQ:MEIP) to "Hold"August 25, 2025 | marketbeat.comMEI Pharma, Inc. (NASDAQ:MEIP) Short Interest Up 12,046.9% in JulyAugust 16, 2025 | marketbeat.comMEI Pharma Welcomes New Board Member Joshua RiezmanAugust 11, 2025 | theglobeandmail.comMEI Pharma files to sell 25.3M shares of common stock for holdersAugust 7, 2025 | msn.comMEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR AdvisingAugust 5, 2025 | joplinglobe.comJMEI Pharma’s Strategic Shift with Litecoin TreasuryJuly 25, 2025 | theglobeandmail.comMEI Pharma's Bold Bet: First Public Company to Go All-In on Litecoin TreasuryJuly 25, 2025 | econotimes.comPublic Shell Firms Ramping Up Altcoin Buys Draws Skepticism: FTJuly 25, 2025 | coindesk.comBTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven modeJuly 24, 2025 | thenewswire.comTMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeJuly 22, 2025 | businesswire.comMEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National ExchangeJuly 20, 2025 | msn.comMEI Pharma Unveils $100M Litecoin Treasury PlanJuly 19, 2025 | livebitcoinnews.comLGSR leads $100M private placement into Nasdaq-listed MEI Pharma to launch Litecoin treasuryJuly 18, 2025 | coinjournal.netMEI Pharma Shares Surge After Unveiling $100 Million Litecoin Treasury PlanJuly 18, 2025 | msn.comMEI Pharma Stock Surges on $100M Private Placement, Litecoin Treasury StrategyJuly 18, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHYPD, MEIP, IVVD, and HURA Company DescriptionsTuHURA Biosciences NASDAQ:HURA$2.52 -0.07 (-2.51%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Hyperion DeFi NASDAQ:HYPD$13.42 +1.43 (+11.93%) As of 03:34 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Invivyd NASDAQ:IVVD$1.40 +0.18 (+14.23%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.MEI Pharma NASDAQ:MEIP$3.19 +0.41 (+14.71%) Closing price 09/10/2025 08:00 PM EasternExtended Trading$3.19 0.00 (0.00%) As of 09/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
